Panelists discuss how KNDy neurons and NK receptors contribute to vasomotor symptoms (VMS) in menopause and explore emerging nonhormonal therapies, including fezolinetant and elinzanetant, for effective symptom management.
EP. 2: VMS Symptoms and Neurokinin Receptor Antagonists
November 25th 2024Panelists discuss how neurokinin 3 (NK3) receptors contribute to vasomotor symptoms (VMS) and how antagonism of NK3 receptors with drugs like fezolinetant can effectively reduce VMS, while also exploring the dual receptor action of elinzanetant, which blocks both NK1 and NK3 receptors to improve VMS and associated sleep disturbances.